Suppr超能文献

相似文献

1
Leveraging the Gut to Treat Metabolic Disease.
Cell Metab. 2020 Apr 7;31(4):679-698. doi: 10.1016/j.cmet.2020.02.014. Epub 2020 Mar 17.
2
The role of bariatric surgery to treat diabetes: current challenges and perspectives.
BMC Endocr Disord. 2017 Aug 10;17(1):50. doi: 10.1186/s12902-017-0202-6.
5
6
The Gut Microbiota as a Mediator of Metabolic Benefits after Bariatric Surgery.
Can J Diabetes. 2017 Aug;41(4):439-447. doi: 10.1016/j.jcjd.2017.02.002. Epub 2017 May 25.
8
The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes.
Cell Metab. 2015 Mar 3;21(3):369-78. doi: 10.1016/j.cmet.2015.01.001. Epub 2015 Feb 5.
10
Gut-adipose tissue crosstalk: A bridge to novel therapeutic targets in metabolic syndrome?
Obes Rev. 2021 Feb;22(2):e13130. doi: 10.1111/obr.13130. Epub 2020 Aug 19.

引用本文的文献

2
Gut microbiota alterations induced by Roux-en-Y gastric bypass result in glucose-lowering by enhancing intestinal glucose excretion.
Gut Microbes. 2025 Dec;17(1):2473519. doi: 10.1080/19490976.2025.2473519. Epub 2025 Mar 3.
3
A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists.
bioRxiv. 2025 Jan 24:2025.01.21.634167. doi: 10.1101/2025.01.21.634167.
4
Smart control lipid-based nanocarriers for fine-tuning gut hormone secretion.
Sci Adv. 2024 Dec 13;10(50):eadq9909. doi: 10.1126/sciadv.adq9909.
5
Description and functional validation of human enteroendocrine cell sensors.
Science. 2024 Oct 18;386(6719):341-348. doi: 10.1126/science.adl1460. Epub 2024 Oct 17.
6
Obesity and the gut microbiota: implications of neuroendocrine and immune signaling.
FEBS J. 2025 Mar;292(6):1397-1420. doi: 10.1111/febs.17249. Epub 2024 Aug 19.
7
A small intestinal bile acid modulates the gut microbiome to improve host metabolic phenotypes following bariatric surgery.
Cell Host Microbe. 2024 Aug 14;32(8):1315-1330.e5. doi: 10.1016/j.chom.2024.06.014. Epub 2024 Jul 22.
8
Gut hormone stimulation as a therapeutic approach in oral peptide delivery.
J Control Release. 2024 Sep;373:31-37. doi: 10.1016/j.jconrel.2024.07.007. Epub 2024 Jul 8.
10
Intestinal epithelial adaptations to vertical sleeve gastrectomy defined at single-cell resolution.
Genomics. 2024 Mar;116(2):110805. doi: 10.1016/j.ygeno.2024.110805. Epub 2024 Feb 1.

本文引用的文献

1
Beyond Glucagon-like Peptide-1: Is G-Protein Coupled Receptor Polypharmacology the Path Forward to Treating Metabolic Diseases?
ACS Pharmacol Transl Sci. 2018 Jun 28;1(1):3-11. doi: 10.1021/acsptsci.8b00009. eCollection 2018 Sep 14.
2
Pharmacological Modulation of Ghrelin to Induce Weight Loss: Successes and Challenges.
Curr Diab Rep. 2019 Sep 10;19(10):102. doi: 10.1007/s11892-019-1211-9.
3
Remission of Type 2 Diabetes Mellitus after Bariatric Surgery: Fact or Fiction?
Int J Environ Res Public Health. 2019 Aug 30;16(17):3171. doi: 10.3390/ijerph16173171.
4
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
Cell Metab. 2019 Nov 5;30(5):987-996.e6. doi: 10.1016/j.cmet.2019.07.013. Epub 2019 Aug 22.
5
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.
6
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9.
9
The incretin system in healthy humans: The role of GIP and GLP-1.
Metabolism. 2019 Jul;96:46-55. doi: 10.1016/j.metabol.2019.04.014. Epub 2019 Apr 25.
10
Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway.
Diabetes. 2019 Jun;68(6):1329-1340. doi: 10.2337/db18-1009. Epub 2019 Apr 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验